2023. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s176. DOI:https://doi.org/10.25251/skin.7.supp.176.